Pre- and Postexposure Use of Human Monoclonal Antibody against H5N1 and H1N1 Influenza Virus in Mice: Viable Alternative to Oseltamivir

W. Koudstaal, M.H. Koldijk, J.P.J. Brakenhoff, A.H.M. Cornelissen, G.J. Weverling, R.H.E. Friesen, J. Goudsmit

    Research output: Contribution to journalArticleAcademicpeer-review

    37 Citations (Scopus)

    Abstract

    New strategies to prevent and treat influenza virus infections are urgently needed. A recently discovered class of monoclonal antibodies (mAbs) neutralizing an unprecedented spectrum of influenza virus subtypes may have the potential for future use in humans. Here, we assess the efficacies of CR6261, which is representative of this novel class of mAbs, and oseltamivir in mice. We show that a single injection with 15 mg/kg CR6261 outperforms a 5-day course of treatment with oseltamivir (10 mg/kg/day) with respect to both prophylaxis and treatment of lethal H5N1 and H1N1 infections. These results justify further preclinical evaluation of broadly neutralizing mAbs against influenza virus for the prevention and treatment of influenza virus infections.
    Original languageEnglish
    Pages (from-to)1870-1873
    JournalThe Journal of Infectious Diseases
    Volume200
    Issue number12
    DOIs
    Publication statusPublished - 2009

    Keywords

    • resistance
    • infection
    • h9n2

    Fingerprint Dive into the research topics of 'Pre- and Postexposure Use of Human Monoclonal Antibody against H5N1 and H1N1 Influenza Virus in Mice: Viable Alternative to Oseltamivir'. Together they form a unique fingerprint.

    Cite this